title: Incidence and clinical impact of stent fracture after the Nobori biolimus-eluting stent implantation.
abstract: BACKGROUND
  Stent fracture (SF) after drug-eluting stent implantation has become an important concern. The aim of this study was to assess the incidence, predictors, and clinical impact of SF after biolimus-eluting stent.
  
  
  RESULTS
  A total of 1026 patients with 1407 lesions undergoing the Nobori biolimus-eluting stent implantation and follow-up angiography within 9 months after index procedure were analyzed. SF was defined as complete or partial separation of the stent, as assessed by using plain fluoroscopy, intravascular ultrasound, or optical coherence tomography during the follow-up. We assessed the rate of SF and the cumulative incidence of clinically driven target lesion revascularization and definite stent thrombosis within 9 months. SF was observed in 58 (4.1%) of 1407 lesions and 57 (5.5%) of 1026 patients. Lesions with hinge motion (OR 8.90, 95% CI 3.84 to 20.6, P<0.001), tortuosity (OR 4.16, 95% CI 1.75 to 9.88, P=0.001), and overlapping stents (OR 2.41, 95% CI 0.95 to 6.10, P=0.06) were predictors of SF. Cumulative incidence of clinically driven target lesion revascularization within 9 months was numerically higher in the SF group than that in the non-SF group (12.0% versus 1.0%). Cumulative incidence of definite stent thrombosis within 9 months tended to be higher in the SF group than that in the non-SF group (1.7% versus 0.5%).
  
  
  CONCLUSIONS
  SF after biolimus-eluting stent occurs in 4.1% of lesions and appears to be associated with clinically driven target lesion revascularization.
authors.affiliation: Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
authors.forename: Shoichi
authors.initials: S
authors.lastname: Kuramitsu
authors.forename: Masashi
authors.initials: M
authors.lastname: Iwabuchi
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Yokoi
authors.forename: Takenori
authors.initials: T
authors.lastname: Domei
authors.forename: Shinjo
authors.initials: S
authors.lastname: Sonoda
authors.forename: Takashi
authors.initials: T
authors.lastname: Hiromasa
authors.forename: Takashi
authors.initials: T
authors.lastname: Morinaga
authors.forename: Yohei
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Kensuke
authors.initials: K
authors.lastname: Ohe
authors.forename: Kaoru
authors.initials: K
authors.lastname: Goya
authors.forename: Kyohei
authors.initials: K
authors.lastname: Yamaji
authors.forename: Makoto
authors.initials: M
authors.lastname: Hyodo
authors.forename: Yoshimitsu
authors.initials: Y
authors.lastname: Soga
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Kondo
authors.forename: Shinichi
authors.initials: S
authors.lastname: Shirai
authors.forename: Kenji
authors.initials: K
authors.lastname: Ando
authors.forename: Koyu
authors.initials: K
authors.lastname: Sakai
authors.forename: Masakiyo
authors.initials: M
authors.lastname: Nobuyoshi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D016009:Chi-Square Distribution; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D023903:Coronary Restenosis / Q000453:epidemiology; D003328:Coronary Thrombosis / Q000453:epidemiology; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation*; D011474:Prosthesis Design; D011475:Prosthesis Failure; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
chemical_list: D002317:Cardiovascular Agents; C518022:umirolimus; D020123:Sirolimus
keywords: biolimus‐eluting stent; drug‐eluting stent fracture; in‐stent restenosis; percutaneous coronary intervention